July 11 (Reuters) - ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concerns. (Reporting by Raghav Mahobe in Bengaluru; Editing by Sriraj Kalluvila)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
These proven wealth builders could be exactly what you're searching for right now.
These three tech stocks look like reliable long-term winners.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Nvidia and Super Micro Computer have been the best-performing S&P 500 stocks of 2024, but select Wall Street analysts still see substantial upside for shareholders.